Every Cure, an organization dedicated to finding existing drugs that could potentially cure hard-to-treat diseases, has gained a valuable new ally in Janet Woodcock. Woodcock, who was a prominent figure at the Food and Drug Administration for many years, recently joined the organization’s board.
The driving force behind Every Cure is physician David Fajgenbaum, who has a personal connection to the mission of the organization. As a young medical student, Fajgenbaum was diagnosed with a rare and life-threatening disease that left him weak and on the brink of death multiple times. After extensive research, he and his doctors discovered that the transplant medicine sirolimus could put his disease into remission, ultimately saving his life.
Initially focused on advocating for patients with Castleman disease, Fajgenbaum’s efforts expanded to include a wide range of rare diseases. Every Cure now aims to identify existing drugs that have the potential to treat these challenging conditions and provide hope for patients in need.
With Woodcock’s expertise and experience in drug regulation and approval, her addition to the board brings valuable insight and guidance to Every Cure. Her knowledge of the pharmaceutical industry and regulatory processes will undoubtedly strengthen the organization’s efforts to identify and repurpose existing drugs for the treatment of rare diseases.
As Every Cure continues its mission to find new treatments and potential cures for hard-to-treat diseases, Woodcock’s involvement promises to enhance the organization’s impact and bring new opportunities for advancing medical research and patient care. It is clear that with dedicated individuals like Fajgenbaum and Woodcock at the helm, Every Cure is poised to make a significant difference in the lives of those affected by rare diseases.
